Conditions: Impaired Glucose Tolerance Oxidative Stress Prediabetes Impaired Fasting Glucose
Keywords: impaired glucose tolerance prediabetes dietary glycemic index beta-cell function insulin secretion oxidative stress glycemic variability
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 56
Healthy volunteers: no

Brief summary:
The study will determine if increasing the highs and lows of blood glucose levels (glycemic variability) impairs insulin secretion in people with impaired glucose tolerance and/or impaired fasting glucose who are at risk for developing type 2 diabetes. Furthermore, the study will determine whether changes in beta-cell function are associated with glycemic variability and whether they are mediated by oxidative stress. To decrease or increase glycemic variability the study will provide subjects with special diets containing either low or high glycemic index foods respectively for 4 weeks. To determine if oxidative stress is a mediator, subjects on the high glycemic index diet will take either placebo or the anti-oxidant N-acetylcysteine. The study will address the hypothesis that increased glycemic variability results in increased oxidative stress and thereby exacerbates beta-cell dysfunction in individuals with impaired glucose tolerance and/or impaired fasting glucose. The findings may have important implications for the development of effective strategies aimed at the prevention and treatment of type 2 diabetes. In addition, understanding the contribution of dietary glycemic index to beta-cell dysfunction in subjects with pre-diabetes may have a significant public health impact, including changes to dietary counseling and promotion of healthier eating patterns.

Detailed description:
Type 2 diabetes is a major health problem in the United States affecting millions of people. It is caused by failure of the pancreatic beta-cells to secrete enough insulin resulting in high blood glucose levels. People with impaired glucose tolerance (IGT) and impaired fasting glucose have elevated glucose levels and are at increased risk for progressing to type 2 diabetes. The long-term objectives of this research are to better understand the factors that contribute to the loss of beta-cell function and impaired insulin secretion. High glucose levels have been shown to impair beta-cell function by causing oxidative stress, and oscillating high glucose levels increase oxidative stress even more than continuous high glucose. Diets containing foods with a high glycemic index (GI) increase the glycemic load (GL) of the diet and post-prandial glucose levels. Therefore, high GL (HGL) diets could be potentially damaging to the beta-cell by increasing glucose fluctuations and oxidative stress. Conversely, low GL (LGL) diets may be beneficial. The study explores the hypothesis that increased glycemic variability results in increased oxidative stress and thereby exacerbates beta-cell dysfunction in people with pre-diabetes.

Specific Aim 1: Determine if a HGL diet worsens and a LGL diet improves beta-cell function compared to a baseline control diet in subjects with pre-diabetes.

Specific Aim 2: Determine if increased glycemic variability on the HGL diet is associated with decreased beta-cell function and conversely if decreased glycemic variability on the LGL diet is associated with improved beta-cell function in subjects with pre-diabetes.

Specific Aim 3: Determine if oxidative stress induced by a HGL diet mediates decreases in beta-cell function by determining if 1) systemic markers of oxidative stress are associated with beta-cell function; 2) if the relationship between glycemic variability and beta-cell function is at least partially explained by oxidative stress; and 3) the anti-oxidant N-acetylcysteine (NAC) prevents decreases in beta-cell function on a HGL diet.

Study design: The study will be a randomized, parallel-design feeding study in men and women with pre-diabetes. Subjects will be randomly assigned to one of 3 separate arms (n=20/arm): 1) 4 weeks on a LGL diet (GI\<35); 2) 4 weeks on a HGL diet (GI\>70) + placebo twice daily; or 3) 4 weeks on a HGL diet (GI\>70) + NAC 1200 mg twice daily. Subjects will be studied after a 2 week baseline control diet with a moderate glycemic load (GI 55-58) for comparison and all diets will be weight stable with the same macronutrient composition (55% carbohydrate/30% fat/15% protein). Beta-cell function will be assessed by both a frequently sampled intravenous glucose tolerance test and a meal test. Glycemic variability will be assessed by a Continuous Glucose Monitoring System and glycemic control by fructosamine. Markers of oxidative stress will be measured.

Arms:
arm 1: low glycemic index diet arm 2: high glycemic index diet plus placebo arm 3: high glycemic index diet plus N-acetylcysteine

Interventions: intervention 1: low glycemic index (LGI) diet intervention 2: high glycemic index (HGI) diet plus placebo (PLAC) intervention 3: high glycemic index diet plus N-acetylcysteine
Intervention descriptions: intervention 1: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable low glycemic index diet (glycemic index \<35) for 4 weeks with all food provided by the Human Nutrition Lab intervention 2: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index \>70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take placebo capsules (matching for active N-acetylcysteine (NAC) in arm 3) twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded. intervention 3: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index \>70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take N-acetylcysteine (NAC) two 600 mg capsules twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.

Protocol document:
Prot_SAP_000.pdf: 
 
1
 
PROTOCOL 
 
Title: Effect of Dietary Glycemic Index on Beta-cell Function 
PI: Kristina Utzschneider, MD 
Co-investigator: Marian Neuhouser 
 
 
NCT01386645 
 
Date: April 2,2014 


 
2
INTRODUCTION AND RATIONALE 
Beta-cell secretory dysfunction is a critical feature of type 2 diabetes mellitus (T2DM) [1] and is 
already present in subjects with pre-diabetes (impaired glucose tolerance (IGT) and/or impaired 
fasting glucose (IFG)) [2-10]. Both IGT and IFG increase the risk of future development of type 2 
diabetes [11]. Hyperglycemia itself can exacerbate beta-cell dysfunction [12, 13] with oxidative stress 
proposed as a major mediator of this “glucotoxic” effect [13]. Further, it has been suggested that 
glucose fluctuations, frequently referred to as “glycemic variability”, may be more harmful than chronic 
sustained hyperglycemia in inducing oxidative stress [14, 15] and therefore could be important with 
regard to deteriorating beta-cell function. However, there are no data specifically examining whether 
glycemic variability contributes to deterioration of beta-cell function. 
 
One way to modulate glycemic variability is to vary dietary glycemic load using foods with either a 
high or low glycemic index (HGI or LGI). Low glycemic load (LGL) diets result in lower post-prandial 
glucose levels (see preliminary data and [16-19]) and improved glycemic control in patients with 
T2DM [20, 21]. Post-prandial glucose levels are the main factor influencing glycemic variability in 
T2DM patients [22]. Short term studies suggest that LGL diets decrease glycemic variability in 
subjects with IGT or T2DM [23-25] and decrease oxidative stress in healthy subjects [18, 19]. Dietary 
advice to follow a LGL diet has also been shown to improve beta-cell function in subjects with IGT 
[26] and T2DM [27], but whether or not this is due to a decrease in glycemic variability is not known. 
Furthermore, whether high glycemic load (HGL) diets worsen beta-cell function has not been tested. 
Hypothesis: Increased glycemic variability results in increased oxidative stress and thereby 
exacerbates beta-cell dysfunction in individuals with pre-diabetes.  
To examine this hypothesis we plan to experimentally manipulate post-prandial glucose excursions 
using HGL and LGL diets in a 4-week controlled dietary intervention during which we will measure 
changes in oxidative stress and beta-cell function. Further, to determine whether oxidative stress is 
an important mechanism whereby a HGL diet and increased glycemic variability contribute to beta-
cell dysfunction, we will treat a subset of subjects with the anti-oxidant N-acetylcysteine (NAC) to 
determine whether NAC can prevent beta-cell dysfunction. We propose to study subjects with pre-
diabetes as they already manifest defects in beta-cell function and therefore are more likely to 
demonstrate further deterioration on a HGL diet or improvement on a LGL diet. Furthermore, they are 
a population that is highly relevant as they are at high risk of developing T2DM.  
Specific Aim 1: To determine if a HGL diet worsens and a LGL diet improves beta-cell function 
compared to a baseline control diet in subjects with pre-diabetes.  
Specific Aim 2: To determine if increased glycemic variability produced by a HGL diet is associated 
with decreased beta-cell function, and conversely if decreased glycemic variability on a LGL diet is 
associated with improved beta-cell function in subjects with pre-diabetes.  
Specific Aim 3: To determine if oxidative stress induced by a HGL diet mediates reductions in beta-
cell function by examining if 1) systemic markers of oxidative stress are associated with beta-cell 
function; 2) the relationship between glycemic variability and beta-cell function is at least partially 
explained by oxidative stress; and 3) the anti-oxidant NAC prevents the reduction in beta-cell function 
on a HGL diet. 
RESEARCH DESIGN AND METHODS 
Overview: The study will be a randomized, parallel-design feeding study in men and women with pre-
diabetes. Subjects will be randomly assigned to one of 3 separate arms (n=20 subjects/arm): 1) 4 
weeks on a LGL diet (glycemic index [GI] <35); 2) 4 weeks on a HGL diet (GI >70) + placebo twice 
daily; or 3) 4 weeks on a HGL diet (GI >70) + NAC 1200 mg twice daily. The placebo vs. NAC arms 
will be double-blinded. Subjects will be studied after a 2 week baseline control diet with a moderate 
glycemic load (GI 55-58) for comparison and all diets will be weight stable with the same 


 
3
macronutrient composition (55% carbohydrate/30% fat/15% protein). Beta-cell function will be 
assessed by both a frequently sampled intravenous glucose tolerance test (IVGTT) and a meal test. 
Glycemic variability and mean glucose levels will be assessed by a 3 day Continuous Glucose 
Monitoring System (CGMS) and glycemic control by fructosamine. Markers of oxidative stress, 
vascular endothelial function and inflammation and incretin hormone levels will be measured. A stool 
sample will be collected to assess changes in the gut microbiome on the diets. Acetaminophen 
absorption will be assessed during the meal test to assess changes in gastric emptying.  
 
 
 
 
 
 
 
 
Study design: The study will be a randomized, parallel design, controlled feeding study of subjects 
with pre-diabetes. Randomization will be stratified by sex. The randomization code will be computer 
generated and kept by the study coordinator. Because the LGL and HGL diets will vary dramatically 
in food content, it will be impossible to blind subjects to diet assignment, but both subjects and 
investigators will be blinded to whether they receive NAC or placebo while on the HGL diet. Subjects 
will undergo study procedures after 2 weeks on a control diet (baseline) and after 4 weeks on the 
intervention diets (Figure 1). Menstruating women will be studied during the follicular phase of their 
menstrual cycle. 
Subjects:  
Inclusion criteria: We will enroll 20 subjects in each study arm (3 arms) with a goal to complete 
studies on 15 subjects/study arm. We conservatively estimate a drop-out rate of 25%. We will enroll 
and study subjects with documented IGT (2 hour glucose 140-199 mg/dl after a standard 75 gram 
OGTT) and/or IFG (fasting plasma glucose 100-115 mg/dl and 2 hour glucose >100 mg/dl). Both men 
and women, age 18-65 years will be eligible. 
Exclusion criteria: Diabetes, alanine aminotransferase (ALT) >1.5 times the upper limit of normal, 
hematocrit <33%, creatinine >1.5 men or >1.3 women, multiple food allergies or intolerances, other 
serious medical or inflammatory conditions, pregnancy or lactation and tobacco use. Subjects will be 
excluded if they take medications that affect insulin sensitivity and secretion (niacin, diabetes 
medications or glucocorticoids) or inflammation (anti-inflammatories). People with significant 
gastroesophageal reflux, swallowing problems or stomach ulcers, including those taking medication 
 


 
4
for these indications, will be excluded as this is a contra-indication for use of NAC. Subjects taking 
other investigational drugs currently or within the past 30 days will not be enrolled. Subjects with 
fasting glucose >115 mg/dl will be excluded as they have typically lost the first phase insulin response 
[28] and that would preclude the ability to detect a decrease during the study.  
Recruitment: The VA, Group Health Cooperative and the UW outpatient clinics in the greater Seattle 
area have large numbers of patients who are at risk for glucose intolerance. Using the electronic 
record we will be able to identify and contact patients who have had an HbA1c of 5.8-6.8% within the 
past three years and who meet all other inclusion/exclusion criteria. We will also recruit subjects with 
known pre-diabetes who have undergone OGTT screening for other research studies being 
conducted by the PI. We will recruit from subjects who are part of the Diabetes Registry as well as the 
Diabetes Endocrinology Research Center (DERC) Registry. We will also use direct advertising 
targeting subjects who may be at risk for pre-diabetes (such as people who are obese, have a history 
of gestational diabetes or a family history of T2DM) utilizing ads and fliers posted at the VA medical 
center in Seattle as well as in local newspapers and on bulletin boards in the greater Seattle area and 
on-line. We will also send mailings with a letter and fliers to local physicians for referral of interested 
patients with pre-diabetes.   
Study procedures: 
Screening: Subjects will undergo an initial brief telephone screening to determine if they may be 
eligible for the study. Subjects who come in for the screening visit will provide written informed 
consent and undergo a history and physical exam, blood draw (hematocrit, creatinine, ALT, glucose, 
and TSH if the subject is on thyroid replacement medication or has a history of thyroid problems or if 
there is clinical concern for possible abnormal thyroid function during the screening exam.) and a 75 
gram OGTT. They will sample study foods and review the menu to ensure that they will be able to 
tolerate the diets. Eligible subjects will undergo the following interventions and procedures (as 
illustrated in Figure 1). 
Diets: All study diets will contain the same nutrient composition (55% energy from carbohydrate/30% 
fat/15% protein) and similar percentages of saturated fat, mono-unsaturated fatty acids (MUFA) and 
poly-unsaturated fatty acids (PUFA), fructose, vitamin E and vitamin C. Fiber content will vary as this 
is inextricably bound with the glycemic index of foods. The average daily GI for each diet will be 55-58 
for the 2 week baseline control diet, >70 for the HGL diet and <35 for the LGL diet. The diets have 
already been developed by the Fred Hutchinson Cancer Research Center (FHCRC) Human Nutrition 
Lab using the 2002 international table of glycemic index and glycemic load values [29]. These diets 
have been used in a previous diet study and were well tolerated. Subjects will come to the Human 
Nutrition Lab twice weekly to be weighed and to pick up their food. Individual energy requirements will 
be calculated using the Mifflin-St. Jeor formula adjusted for activity level. Subjects will be given 
individualized dietary instructions to keep their weight stable and told to maintain their usual level of 
physical activity. Subjects will be weighed twice a week when they come to pick up their food and the 
diets will be adjusted in 200 calorie increments if needed to maintain a stable weight. They will be told 
not to take any vitamins (including multivitamins) throughout the duration of the study as these may 
impact our measures of oxidative stress.   
Drug: Subjects on the HGL diet will take either NAC 1200 mg (two 600 mg capsules) orally twice 
daily or matching placebo capsules orally twice daily. NAC and matching placebo capsules will be 
obtained from Twinlabs (Utah). If study subjects are not able to tolerate the 1200 mg twice daily dose, 
the dose will be decreased to 600 mg twice daily. If this were to occur one of the study staff would 
follow-up with the study subject by phone within 5 days of the change in dose to assess for side-
effects. NAC is FDA approved as a mucolytic agent and for treatment of acetaminophen overdose 
and is also available over-the-counter as a dietary supplement. It is rapidly absorbed with peak 
plasma levels occurring after approximately 1 hour. We will monitor for drug activity by measuring 
erythrocyte GSH and GSSG levels.   


 
5
Compliance: Dietary compliance will be monitored by having subjects check each food they eat on a 
daily menu. They will be asked to note, in as much detail as possible, all deviations from the study 
regimen on these daily food records. They will also be asked to return all food they might not be able 
or willing to eat. Any returned food will be weighed by the Human Nutrition Lab for accurate 
assessment of quantity and quality of foods that were actually consumed. Drug compliance will be 
monitored by having subjects on the HGL diet return any unused capsules at the end of the 4 week 
intervention period. Subjects who take <80% of the study medication will be considered as drop-outs 
and will be replaced.  
Nutrition visit: Subjects will report to the Human Nutrition Lab two weeks before starting the control 
diet period to review and sign Nutrition visit consent form, review their 3-day food record, measure 
body weight and calculate caloric needs.  
Study procedures: All study procedures will be performed while on the control diet and again while 
on the intervention diet (see Figure 1). The IPAQ will be performed at the nutrition visit as well as on 
the CGMS days. Subjects will be instructed to avoid taking vitamins or anti-inflammatory medications 
during the study.  
CGMS: The CGMS (iPro by Medtronic, Northridge CA) will be inserted by trained study staff and 
subjects will receive instruction on its use and care. The CGMS will be removed 3 days later at the 
time of the IVGTT. The iPro provides blinded interstitial glucose profiles. Subjects will also be 
instructed to keep a daily food and physical activity diary (such as time and type of exercise 
performed or food consumed) for the 3 days that they are wearing the CGMS. For proper calibration 
of the CGMS, subjects will be provided with a glucometer (ACCU-CHEK Aviva) and instructed to 
check their fingerstick blood glucose four times daily for the 3 days while they are wearing the CGMS. 
The CGMS will be removed by study staff before the IVGTT is performed and the data downloaded 
and analyzed using iPro software. The mean glucose levels as well as the SD are calculated by the 
iPro software. The MAGE will be calculated as described by Service et al [30]. 
IPAQ: The international physical activity questionnaire (IPAQ) [31] will be administered to monitor and 
adjust for changes in physical activity on the control diet and at the end of the intervention diet. 
Subjects will be told to try to maintain a stable activity level throughout.  
Stool sample: Because changes in the stool microbiota may be associated with inflammation and 
could be altered by changes in diet composition, subjects will be asked to collect a stool sample 
during the last few days on the control and intervention diets. Subjects will be provided with stool 
sample collection kits and detailed instructions.  
Fasting urine sample: One aliquot will be sent to the clinical lab for measurement of urine creatinine 
and a second aliquot will be frozen at -80°C for subsequent measurement of F2 -isoprostanes by gas 
chromatography/mass spectrometry (GC/MS). A urine pregnancy test will be performed in women 
with child-bearing potential. 
IVGTT: Subjects will arrive after at least a 12 hour overnight fast. An insulin-modified IVGTT will be 
performed as we have done previously [32]. For subjects on the HGL diet, they will take study 
medication (either NAC or placebo) 30 minutes prior to glucose injection. The sampling arm will be 
wrapped in a heating pad to “arterialize” the blood. After obtaining 3 baseline samples, 50% dextrose 
(11.4 mg/body surface area) will be administered intravenously over 60 seconds. From 20-25 minutes 
post glucose injection, insulin (0.03 units/kg) will be infused. Blood samples will be drawn for glucose 
and insulin at 35 time points over 240 minutes. 
Meal test: The meal test will immediately follow the IVGTT. Subjects will consume a standardized 
lunch meal containing 75 grams carbohydrate and the same glycemic index and macronutrient 
composition the subject has been eating. Acetaminophen 1.5 grams (given as 3 x 500 mg tablets with 
water) will be given at the start of the test meal. The test meal will be consumed within 15 minutes. 


 
6
Blood will be drawn for glucose, insulin, C-peptide, total GLP-1, total GIP and free fatty acid 
measurements at -10, -5, -1, 10, 20, 30, 60, 90, 120, 180 and 240 minutes after the start of the meal. 
Plasma nitrotyrosine, endothelial and inflammatory markers will be measured at -1, 60, 120, 180 and 
240 minutes. Acetaminophen levels will be measured at 0, 30, 60, 90, 120, 180 and 240 minutes to 
estimate gastric emptying. Blood will be collected at -30, -1, 60, 120, 180 and 240 minutes for the 
erythrocyte GSH and GSSG assays. Computer modeling of the meal test data will be performed 
using SAAM II software under the guidance of David Foster. 
Safety Assessment: A side-effect questionnaire will be utilized to assess for side-effects from the 
diets or NAC. This will be performed twice, once before starting the study diet +/- NAC and again after 
four weeks on the study diet +/- NAC. An independent safety officer will be appointed to review safety 
data every 6 months. The safety officer will be notified in the event of pregnancy, an unanticipated 
adverse event or a serious adverse event, in addition to the IRB. Women with child-bearing potential 
will undergo a urine pregnancy test.  
Study withdrawal criteria: Subjects will be withdrawn from the study if they develop serious or 
intolerable side-effects from study medications or study diets, development of any serious medical 
condition during the study or pregnancy. Subjects who are not compliant with the protocol will also be 
withdrawn. 
Study stopping rules: The appointed safety officer will make the decision to stop the study 
prematurely if he/she determines that there are serious side-effects associated with the study.  
Primary endpoints:  
- 
The disposition index (insulin sensitivity index [SI] x AIRg) from the IVGTT  
Secondary endpoints: 
- 
The disposition indices (static, dynamic and total beta-cell responsivity [Φ] x SI MT) derived 
from minimal modeling of the meal test [33] 
- 
Glycemic variability measured by CGMS: SD of glucose and MAGE 
- 
Mean glucose from the CGMS 
- 
Post prandial glucose AUC (0-240 minutes) during the meal test 
- 
Plasma fructosamine levels 
- 
Markers of oxidative stress including urine isoprostanes, plasma nitrotyrosine and plasma 
protein carbonyls 
- 
Anti-oxidant status: Total plasma anti-oxidant capacity and erythrocyte GSH and GSSG levels 
and the GSH/GSSG ratio 
- 
Insulin sensitivity: SI will be determined from data from the IVGTT using Bergman’s minimal 
model [34] and SI MT will be determined from the meal test data using the model developed by 
Cobelli [33] 
- 
AIRg will be calculated as the incremental insulin response from 0-10 minutes after glucose 
injection during the IVGTT  
- 
Markers of inflammation including TNFα, IL-6, MCP-1, PAI-1, IL-1β 
- 
Markers of endothelial function including VCAM, ICAM-1 and endothelin-1 
- 
Free fatty acids levels during the meal test 
- 
Plasma acetaminophen levels (maximal concentration and area under the curve) as a 
measure of gastric emptying 
- 
Stool microbiota profiles 
- 
Incretin hormone levels during the meal test (GIP and GLP-1) 
Sample size calculations: Sample sizes were calculated using Stata (Version 9.1). For computation 
of samples sizes for the IVGTT we used data from repeat IVGTTs that yielded a mean disposition 
index of 2517  and a standard deviation for the change in the disposition index of 829 [35]. Sample 
size for Specific aim 1 was calculated for a one-sample comparison (paired test) with two-sided 


 
7
α=0.05 and power=0.80 for the change in disposition index from baseline. Using a sample size of 15 
subjects/arm, we will have 94% power to detect a 30% change in the IVGTT disposition index from 
baseline. For Specific Aim 3, a sample size of 15/group was calculated using a two-sample 
comparison (independent t-test) with one-sided α=0.05 and power=0.80 for comparison of the change 
in the disposition index (intervention – baseline) on the HGL + placebo vs. HGL + NAC. A one-sided α 
was used for Specific Aim 3 as we anticipate that the NAC will lead to an improvement in β-cell 
function. Using a conservative estimate of a drop-out rate of 25% we will enroll 20 subjects in each 
arm to ensure that we complete studies on 15 in each arm. 
Statistical analysis: The data will be tabulated and changes calculated (intervention diet – baseline) 
for each variable. For Specific Aim 1 paired t-test analysis will be used to assess for significant 
changes in each variable between baseline and each diet intervention. Specifically we will determine 
if the LGL diet increases the disposition index compared to the control diet and if the HGL diet + 
placebo decreases the disposition index compared to the control diet. Using general linear model with 
repeated measures we will test for diet group effect adjusting for possible covariates such as changes 
in weight. We will use similar statistical approaches to assess for significant diet effects on other 
measures of beta-cell function, insulin sensitivity, markers of inflammation and oxidative stress and 
glycemic variability. For Specific Aim 2 we will assess the relationship between changes in the 
disposition indices and measures of glycemic variability, post-prandial glucose levels, mean glucose 
and fructosamine levels on the HGL + placebo and LGL diet using simple and multiple linear 
regression analysis. For Specific Aim 3 we will compare changes in the disposition index from 
baseline between the HGL + placebo vs. HGL + NAC arms by independent t-test analysis. The 
relationship between markers of oxidative stress and measures of glycemic variability, glucose levels, 
insulin sensitivity and beta-cell function will be determined using simple and multiple linear regression 
models and Sobel’s test of the mediating role of oxidative stress in the relationship between glycemic 
variability and beta-cell function will be conducted. We will also determine if baseline beta-cell 
function is associated with changes in post-prandial glucose AUC and measures of glycemic 
variability using regression analysis. If baseline beta-cell function predicts the response to the diets, 
we will adjust for this in our final analyses. Exploratory analyses will investigate the effects of the high 
and low GL diets compared to the control diet on gastric emptying, markers of endothelial function, 
the stool microbiome and incretin hormone responses. These changes will be correlated with 
changes in beta-cell function, insulin sensitivity and insulin secretion measures. If any of these 
variables are found to have a significant association with beta-cell function, they will be included in 
the multiple regression models listed above. Regression analyses will also adjust for potential 
confounders such as age, BMI and gender. Data that are not normally distributed will be transformed 
to approximate a normal distribution. A p value <0.05 will be considered significant. 
 
 
 
References 
 
1. 
Kahn, S.E., et al., The beta cell lesion in type 2 diabetes: there has to be a primary functional 
abnormality. Diabetologia, 2009. 52(6): p. 1003-12. 
2. 
Festa, A., et al., The natural course of β-cell function in nondiabetic and diabetic individuals: the Insulin 
Resistance Atherosclerosis Study. Diabetes, 2006. 55(4): p. 1114-20. 
3. 
Byrne, M.M., et al., Elevated plasma glucose 2 h postchallenge predicts defects in ß-cell function. Am J 
Physiol, 1996. 270(4 Pt 1): p. E572-9. 
4. 
Ehrmann, D.A., et al., Insulin secretory responses to rising and falling glucose concentrations are 
delayed in subjects with impaired glucose tolerance. Diabetologia, 2002. 45(4): p. 509-17. 
5. 
Breda, E., et al., Insulin release in impaired glucose tolerance: oral minimal model predicts normal 
sensitivity to glucose but defective response times. Diabetes, 2002. 51 Suppl 1: p. S227-33. 


 
8
6. 
Ferrannini, E., et al., Beta-cell function in subjects spanning the range from normal glucose tolerance to 
overt diabetes: a new analysis. J Clin Endocrinol Metab, 2005. 90(1): p. 493-500. 
7. 
Gastaldelli, A., et al., Beta-cell dysfunction and glucose intolerance: results from the San Antonio 
metabolism (SAM) study. Diabetologia, 2004. 47(1): p. 31-9. 
8. 
Utzschneider, K.M., et al., Impact of differences in fasting glucose and glucose tolerance on the 
hyperbolic relationship between insulin sensitivity and insulin responses. Diabetes Care, 2006. 29(2): p. 
356-62. 
9. 
Jensen, C.C., et al., ß-cell function is a major contributor to oral glucose tolerance in high-risk relatives 
of four ethnic groups in the U.S. Diabetes, 2002. 51(7): p. 2170-8. 
10. 
Kanat, M., et al., Impaired early- but not late-phase insulin secretion in subjects with impaired fasting 
glucose. Acta Diabetol, 2011. 48(3): p. 209-17. 
11. 
de Vegt, F., et al., Relation of impaired fasting and postload glucose with incident type 2 diabetes in a 
Dutch population: The Hoorn Study. JAMA, 2001. 285(16): p. 2109-13. 
12. 
Boden, G., et al., Effects of prolonged glucose infusion on insulin secretion, clearance, and action in 
normal subjects. Am J Physiol, 1996. 270(2 Pt 1): p. E251-8. 
13. 
Poitout, V. and R.P. Robertson, Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev, 
2008. 29(3): p. 351-66. 
14. 
Ceriello, A., et al., Oscillating glucose is more deleterious to endothelial function and oxidative stress 
than mean glucose in normal and type 2 diabetic patients. Diabetes, 2008. 57(5): p. 1349-54. 
15. 
Monnier, L., et al., Activation of oxidative stress by acute glucose fluctuations compared with sustained 
chronic hyperglycemia in patients with type 2 diabetes. Jama, 2006. 295(14): p. 1681-7. 
16. 
Bouche, C., et al., Five-week, low-glycemic index diet decreases total fat mass and improves plasma 
lipid profile in moderately overweight nondiabetic men. Diabetes Care, 2002. 25(5): p. 822-8. 
17. 
Wolever, T.M. and C. Mehling, Long-term effect of varying the source or amount of dietary 
carbohydrate on postprandial plasma glucose, insulin, triacylglycerol, and free fatty acid 
concentrations in subjects with impaired glucose tolerance. Am J Clin Nutr, 2003. 77(3): p. 612-21. 
18. 
Dickinson, S., et al., High-glycemic index carbohydrate increases nuclear factor-kappaB activation in 
mononuclear cells of young, lean healthy subjects. Am J Clin Nutr, 2008. 87(5): p. 1188-93. 
19. 
Botero, D., et al., Acute effects of dietary glycemic index on antioxidant capacity in a nutrient-controlled 
feeding study. Obesity (Silver Spring), 2009. 17(9): p. 1664-70. 
20. 
Thomas, D.E. and E.J. Elliott, The use of low-glycaemic index diets in diabetes control. Br J Nutr: p. 1-
6. 
21. 
Livesey, G., et al., Glycemic response and health--a systematic review and meta-analysis: relations 
between dietary glycemic properties and health outcomes. Am J Clin Nutr, 2008. 87(1): p. 258S-268S. 
22. 
Zhou, J., et al., Glycemic variability and its responses to intensive insulin treatment in newly diagnosed 
type 2 diabetes. Med Sci Monit, 2008. 14(11): p. CR552-8. 
23. 
Nansel, T.R., L. Gellar, and A. McGill, Effect of varying glycemic index meals on blood glucose control 
assessed with continuous glucose monitoring in youth with type 1 diabetes on basal-bolus insulin 
regimens. Diabetes Care, 2008. 31(4): p. 695-7. 
24. 
Gellar, L. and T.R. Nansel, High and low glycemic index mixed meals and blood glucose in youth with 
type 2 diabetes or impaired glucose tolerance. J Pediatr, 2009. 154(3): p. 455-8. 
25. 
Brynes, A.E., et al., A low glycemic diet significantly improves the 24-h blood glucose profile in people 
with type 2 diabetes, as assessed using the continuous glucose MiniMed monitor. Diabetes Care, 2003. 
26(2): p. 548-9. 
26. 
Wolever, T.M. and C. Mehling, High-carbohydrate-low-glycaemic index dietary advice improves 
glucose disposition index in subjects with impaired glucose tolerance. Br J Nutr, 2002. 87(5): p. 477-87. 
27. 
Wolever, T.M., et al., Low glycaemic index diet and disposition index in type 2 diabetes (the Canadian 
trial of carbohydrates in diabetes): a randomised controlled trial. Diabetologia, 2008. 51(9): p. 1607-
15. 
28. 
Brunzell, J.D., et al., Relationships between fasting plasma glucose levels and insulin secretion during 
intravenous glucose tolerance tests. J Clin Endocrinol Metab, 1976. 42(2): p. 222-9. 


 
9
29. 
Foster-Powell, K., S.H. Holt, and J.C. Brand-Miller, International table of glycemic index and glycemic 
load values: 2002. Am J Clin Nutr, 2002. 76(1): p. 5-56. 
30. 
Service, F.J., et al., Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes, 
1970. 19(9): p. 644-55. 
31. 
Craig, C.L., et al., International physical activity questionnaire: 12-country reliability and validity. Med 
Sci Sports Exerc, 2003. 35(8): p. 1381-95. 
32. 
Utzschneider, K.M., et al., The Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves β-cell Function 
and Insulin Sensitivity in Subjects with Impaired Fasting Glucose. Diabetes Care, 2007. 
33. 
Dalla Man, C., et al., Two-hour seven-sample oral glucose tolerance test and meal protocol: minimal 
model assessment of beta-cell responsivity and insulin sensitivity in nondiabetic individuals. Diabetes, 
2005. 54(11): p. 3265-73. 
34. 
Bergman, R.N., L.S. Phillips, and C. Cobelli, Physiologic evaluation of factors controlling glucose 
tolerance in man: measurement of insulin sensitivity and ß-cell glucose sensitivity from the response to 
intravenous glucose. J Clin Invest, 1981. 68(6): p. 1456-67. 
35. 
Abbate, S.L., et al., Effect of heparin on insulin-glucose interactions measured by the minimal model 
technique: implications for reproducibility using this method. Metabolism, 1993. 42(3): p. 353-7.